If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.

Fingerprint Dive into the research topics where David Claxton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 19 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Hematologic Neoplasms Medicine & Life Sciences
Stem Cells Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1989 2019

Targeted Sphingolipid Metabolism for Treatment of AML

Claxton, D., Wang, H., Wang, H., Amin, S., Liao, J. (., Fox, T., Loughran, T. P., Loughran, T. P., Kester, M., Kester, M. & Cabot, M. C.

National Institutes of Health


Project: Research project

Acute Myeloid Leukemia
Acid Ceramidase


Claxton, D., Deisseroth, A., Siciliano, M., Benedict, W., Reading, C., Liang, J., Plunkett, W., Thall, P., Thomas, M., Reed, J., Andreeff, M., Berry, D., Kornblau, S., Croce, C., Estey, E., Nagarajan, L., Deisseroth, A. & Champlin, R. E.

National Institutes of Health


Project: Research project

Core Binding Factors
Transcription Factors
Genetically Modified Animals


Claxton, D., Kurzrock, R., Ming-Sheng, L., Reading, C., Emerson, S., Liang, J., Feinberg, A., Deisseroth, A., Siciliano, M., Kantarjian, H., Talpaz, M., Andreeff, M., Kornblau, S., Thall, P., Issa, J., Estrov, Z., Arlinghaus, R. B., Deininger, M., Shpall, E., Champlin, R., Belmont, J., Reisner, Y., Austin, D., Issa, K. & Cortés, J.

National Institutes of Health


Project: Research project

Dendritic Cells

Research Output 1989 2019

1 Citation (Scopus)

Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation

Tan, S. F., Dunton, W., Liu, X., Fox, T. E., Morad, S. A. F., Desai, D., Doi, K., Conaway, M. R., Amin, S., Claxton, D., Wang, H. G., Kester, M., Cabot, M. C., Feith, D. J. & Loughran, T. P., Jan 1 2019, In : Journal of Lipid Research. 60, 6, p. 1078-1086 9 p.

Research output: Contribution to journalArticle

Acid Ceramidase
Drug Resistance
Acute Myeloid Leukemia
10 Citations (Scopus)

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403

Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., Paietta, E., Parker, E., Geyer, S., Mrózek, K., Bloomfield, C. D., Sanford, B., Marcucci, G., Liedtke, M., Claxton, D., Foster, M. C. & 8 others, Bogart, J. A., Grecula, J. C., Appelbaum, F. R., Erba, H., Litzow, M. R., Tallman, M. S., Stone, R. M. & Larson, R. A., Apr 4 2019, In : Blood. 133, 14, p. 1548-1559 12 p.

Research output: Contribution to journalArticle

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Young Adult
Confidence Intervals
Disease-Free Survival

Downregulation of CD73 associates with T cell exhaustion in AML patients

Kong, Y., Jia, B., Zhao, C., Claxton, D., Sharma, A., Annageldiyev, C., Fotos, J., Zeng, H., Paulson, R., Prabhu, K. S. & Zheng, H., Apr 24 2019, In : Journal of Hematology and Oncology. 12, 1, 40.

Research output: Contribution to journalArticle

Open Access
Acute Myeloid Leukemia
1 Citation (Scopus)
Open Access
Acute Myeloid Leukemia
Transcription Factors
Induction Chemotherapy

Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study

Pu, J. J., Poulose, J., Malysz, J., Zhu, J., Fanburg-Smith, J., Claxton, D. & Bayerl, M., Jan 1 2019, In : British Journal of Haematology. 186, 5, p. e130-e133

Research output: Contribution to journalLetter

Open Access
Primary Myelofibrosis
Stem Cells